Release date: 2016-05-30

In the world of surgical robots, the most famous nowadays is the "Da Vinci" robot. The "Da Vinci" robot was born on January 9, 1999. It was developed by Intuitive Surgical Inc. of the United States. In 2000, it was officially approved by the US FDA for certification. It became the world's first robotic surgery system that can be used in abdominal surgery.

At the same time as the "Da Vinci" robot was launched, the first "small frame neurosurgical robot" was successfully applied to clinical surgery. This "frameless neurosurgical robot" is the predecessor of Remebot.

Remebot has accumulated 18 years of technology

After 18 years of technical accumulation, 15 years of clinical exploration, more than 20,000 clinical surgeries and 6 product iterations, Remebot was officially launched in 2015.

The new generation Remebot neurosurgery robot consists of three parts, a computer software system, a real-time camera and an automatic robot arm, which can also be compared to brain, eye and hand. Before surgery, patients were labeled with special markers for medical imaging. With 3D visualization and multimodal image fusion technology, doctors can clearly and intuitively observe the lesions, their surrounding tissues and blood vessels, and plan the optimal puncture path. At the time of surgery, the patient and the robotic arm must be registered first, and the purpose is to establish a one-to-one mapping relationship between the virtual three-dimensional model and the real scene. After the registration is completed, the robot arm is accurately moved to the pre-planned position under the supervision of the camera. Finally, the doctor completes the puncture and performs biopsy, aspiration, destruction, implantation, and the like. With Remebot, the doctor can complete the operation within 30 minutes, the positioning error is less than 1mm, the patient only leaves a small wound of 2mm, and can be discharged after 2-3 days of postoperative observation.

With the operating platform at the end of the robotic arm, doctors can perform 12 types of surgical procedures such as biopsy, aspiration, destruction, implantation, and radiotherapy for the surgical treatment of nearly 100 diseases such as cerebral hemorrhage, brain cyst, Parkinson's disease, and epilepsy.

Stereotactic frame surgery is a relatively common procedure in neurosurgery before robots are available. The traditional stereotactic Leksell frame requires four holes to be fixed, and the patient needs to wear a frame to scan medical images. In robot-assisted surgery, the patient only needs to stick four markers on the head, which will not cause extra trauma other than the surgical wound. .

According to Wang Tianmiao, there are several advantages to surgical robots. First, liberate doctors' productivity. The key aspects of the surgical plan are controlled by the doctor. Remebot can assist the doctor in accurately positioning and reducing the physical burden of the doctor. Second, the robot can perform remote surgery. Using two networked robots, you can combine the best surgical solutions of your experts with the most accurate positioning of local robots to improve your treatment efficiency. Previously, Remebot had achieved remote surgery in Beijing-Yan'an, Beijing-Shenyang, and was expected to use telesurgery to achieve more successful cases.

However, in clinical surgery, robotic products are only assisting doctors in positioning, and the key aspects such as the development of surgical plans still rely on expert experience.

At present, the price of robotic surgery has certain advantages over traditional stereotactic frame surgery. Cerebral hemorrhage and biopsy: 20,000 to 30,000; Parkinson's and epilepsy damage: less than 50,000; but there are also certain disadvantages, robot positioning, professional consumables. Temporarily not entered the scope of medical insurance reimbursement.

Remebot's industrialization path and planning

According to CEO Liu Da, Remebot has passed the green channel of innovative medical device approval, and has carried out clinical deep cooperation with the top three hospitals such as Tiantan and Xuanwu. The leading role of these hospitals in the academic field will help promote the primary hospitals. Moreover, Remebot can also be customized to a certain extent according to the doctor's clinical needs in the first time to meet the individual needs of different doctors. It is understood that Remebot will establish cooperative relations with about 30 hospitals in various provinces and prefecture-level cities this year.

Baihui Weikang will establish an Internet + medical robot model in each province. The doctors and experts of the Central Hospital support the following hospitals to carry out surgery to achieve the best resources of experts. With the Remebot robot, the expert only uses the core surgical planning part, and the rest is left to the robot and the general practitioner. The expert can complete the surgical planning part in only 3~5 minutes. Through telemedicine, an expert can manage and support multiple hospitals, completing several times a day to complete previous surgical planning online, and the distal end is performed by a general practitioner with the assistance of a robot.

According to the plan, Remebot plans to officially sell to the market after receiving the CFDA approval certificate in the second half of this year. Baihui Weikang expects to sell about 100 Remebots next year. Liu Da told the arterial network that Baihui Weikang has already established a production base in Yizhuang, ready for the mass production of Remebot in advance.

In addition, Remebot is already in the international market.

In the international market, Remebot's competitors are French ROSAs for start-ups, but the penetration rate of this product is not high. Remebot's CE certification has been launched, and the conditions for entering the European market are met after the certification is passed. Especially after telemedicine is opened, product globalization will accelerate.

Another plan of Baihui Weikang is to establish a biopsy center in Beijing, Shanghai and Hangzhou.

"The diagnosis of a tumor cannot be accurately judged by images alone, and biopsy is a safer and more reliable way to confirm." Liu Da told the arterial network that brain biopsy can reach millions of grades per year. Remebot is used for biopsy wounds. Small and efficient. Baihui Weikang cooperated with public hospitals and private hospitals in various places to establish a brain tissue biopsy center. Each operation cost is 20,000, and the annual biopsy operation volume is more than 1,000.

It is worth mentioning that Remebot's core technology - multi-image 3D fusion system and robotic positioning system can not only be used in neurosurgery, but also the killer needs of many other departments in minimally invasive surgery. Baihui Weikang will further plan in this regard in the future. Layout, working with other department doctors to research new products.

Remebot reached a cooperation with Xingshulin and famous doctors

At present, Remebot has already reached a strategic cooperation with Xingshu, the famous doctor and Remebot, and cooperates with medical robots from doctor education and patient education to promote the promotion of this new technology in the professional population and the general public.

The three-party cooperation has a certain connection with one of Remebot's investors.

The Zhenge Fund has invested in a number of medical and health projects, including doctors' learning, the social platform “Xinglin”, and the mobile medical operating platform “Medical Doctor”. "The main users of Apricot Forest are doctors, and the famous doctors are facing patients. Combined with Remebot's technology, the three have a good resource synergy." Li Jianwei told the arterial network.

Li Jianwei said that the real fund chose to invest in Remebot, mainly because of the technical breakthrough in this product. “Neurosurgery robots are more difficult than other robots, and this robot is of great benefit to doctors and hospitals, and is equivalent to an enhanced version of the doctor for doctors.”

Remebot's other investor, Haiquan Fund, comes with a star aura. Have a high level of awareness in the public. Therefore, for the big health project, Haiquan Fund hopes that such projects can be understood and recognized by more patients through its high-quality resources and high exposure. Haiyan Fund co-founder Wang Wei revealed that Haiquan Fund is more concerned about medical testing equipment projects and optimistic about new technology innovation companies.

It is understood that Haiquan Fund was established less than three years ago, and the current fund management scale is 3 billion yuan, with nearly 30 investment projects. Among them, it has successfully invested in many domestic leading medical equipment projects, including the investment in the first domestic glaucoma inspection equipment company, Meikewohua Medical in October 2015; the investment of Meishi Medical has the world's first breast nuclear magnetic resonance system, infant MRI The system has broad market prospects. The investment in Remebot is the third medical testing equipment project of Haiquan Fund. In view of its advantages in assisting doctors to accurately locate, improve surgical efficiency and minimize trauma area, the investment was locked in the initial market.

Source: Arterial Network

Grape Seed Extract

Grape Seed Extract is rich in Oligomers Procyanodolic Complexes (OPC) , which is a powerful antioxidant. In addition to the ultra rich potence of over 20 times higher than Vitamin C, it is also 50 times better than Vitamin E. It helps to strengthen the immune system, and also slowdown the aging process. Grape seed extract is a class of polyphenols extracted and separated from grape seeds, mainly composed of Proanthocyanidins,Polyphenol,Oligomeric Proanthocyanidins,Proanthocyanidin B2.

Grape Seed Extract,Grape Seed Extract Opc,Grape Skin Extract,Grape Seed Extract Procyanidin

XI'AN PLANT BIO-ENGINEERING CO.,LTD , https://www.plantbic.com